Skip to main content
. 2022 Jun 23;43(9):5615–5624. doi: 10.1007/s10072-022-06221-6

Table 1.

Comparison of clinical, neuroimaging and laboratory characteristics of tuberculous myelitis versus other causes of myelitis

Variables All patients N = 52 Tuberculous myelitis N = 18 Other causes of myelitis N = 34 P B-H adjusted P values Relative risk (95% Confidence Interval)
Age in years 0.810 0.810 NA
Mean ± SD 26.94 ± 11.86 25.83 ± 6.48 27.53 ± 13.96
Median (IQR) 26.5 (13.8) 26.00 (5.5) 27.00 (20.5)
Gender Male N (%) 26 (50) 8 (44.4) 18 (52.9) 0.560 0.632 0.8 (0.38–1.70)
Paraparesis N (%) 42 (80.8) 17 (94.4) 25 (73.5) 0.136 0.216 4.05 (0.61–26.93)
Quadriparesis N (%) 10 (19.2) 1 (5.6) 9 (26.5) 0.136 0.238 0.25 (0.04–1.64)
Sensory involvement N (%) 35 (67.3) 8 (44.4) 27 (79.4) 0.011 0.032 0.39 (0.19–0.804)
Sphincter involvement N (%) 47 (90.4) 15 (83.3) 32 (94.1) 0.327 0.424 0.53 (0.23–1.22)
Fever N (%) 18 (34.6) 10 (55.6) 8 (23.5) 0.021 0.057 2.36 (1.13–4.92)
Headache N (%) 11 (21.2) 8 (44.4) 3 (8.8) 0.005 0.018 2.98 (1.56–5.71)
Seizure N (%) 03 (5.8) 2 (11.1) 1 (2.9) 0.543 0.634 2.04 (0.84–5.00)
Vomiting N (%) 09 (17.3) 5 (27.8) 4 (11.8) 0.247 0.360 1.84 (0.88–3.85)
Hiccough N (%) 03 (5.8) 0 (0) 3 (8.8) 0.308 0.414 NA
Vision loss N (%) 04 (7.7) 0 (0) 4 (11.8) 0.285 0.399 NA
Chest X-ray abnormalities (s/o TB) N (%) 9 (17.3) 9 (50.0) 0 (0) 0.001 0.004 NA
T2 hyperintensity in spinal cord N (%) 52 (100.0) 18 (100) 34 (100) NA NA NA
Corresponding T1 hypointensity N (%) 21 (40.4) 8 (44.4) 13 (38.2) 0.664 0.704 1.18 (0.56–2.49)
Cord swelling N (%) 10 (19.2) 1 (5.6) 9 (26.5) 0.136 0.227 0.25 (0.04–1.64)
Spinal meningeal enhancement N (%) 14 (26.9) 14 (77.8) 0 (0)  < 0.001  < 0.001 NA
Arachnoiditis N (%) 3 (5.8) 3 (16.7) 0 (0) 0.037 0.086 NA
CSF loculation N (%) 3 (5.8) 3 (16.7) 0 (0) 0.037 0.081 NA
Extra axial collection 3 (5.8) 3 (16.7) 0 (0) 0.037 0.093 NA
Spinal tuberculoma 2 (3.8) 2 (11.1) 0 (0) 0.115 0.211 NA
Cervical cord involvement N (%) 4 (7.7) 2 (11.1) 2 (5.9) 0.602 0.658 1.50 (0.52–4.32)
Cervico-Dorsal cord involvement N (%) 38 (73.1) 12 (66.7) 26 (76.5) 0.448 0.541 0.74 (0.34–1.58)
Dorsal cord involvement N (%) 10 (19.2) 4 (22.2) 6 (17.6) 0.723 0.744 1.2 (0.50–2.87)
Area postrema involvement N (%) 12 (23.1) 1 (5.6) 11 (32.4) 0.039 0.080 0.20 (0.03–1.32)
LETM N (%) 46 (88.5) 17 (94.4) 29 (85.3) 0.412 0.515 2.22 (0.36–13.80)
Hydrocephalus N (%) 7 (13.5) 7 (38.9) 0 (0)  < 0.001  < 0.001 NA
Basal exudates N (%) 8 (15.4) 8 (44.4) 0 (0)  < 0.001  < 0.001 NA
Tuberculoma N (%) 9 (17.3) 9 (50.0) 0 (0)  < 0.001  < 0.001 NA
Infarct N (%) 2 (3.8) 2 (11.1) 0 (0) 0.113 0.212 NA
Meningeal enhancement N (%) 11 (21.2) 11 (61.1) 0 (0)  < 0.001  < 0.001 NA
Brain demyelination N (%) 5 (9.6) 0 (0) 3 (14.7) 0.150 0.228 NA
CSF protein mg/dl  < 0.001  < 0.001 NA
Mean ± SD 204.30 ± 368.20 403.67 ± 534.15 98.76 ± 171.41
Median (IQR) 70.00 (98.3) 148.50 (501.00) 58.00 (45.8)
CSF glucose mg/dl  < 0.001  < 0.001 NA
Mean ± SD 69.29 ± 30.97 49.89 ± 29.79 79.56 ± 26.66
Median (IQR) 63.50 (44.8) 45.50 (25.8) 69.50 (39.8)
CSF cell/mm3  < 0.001  < 0.001 NA
Mean ± SD 72.75 ± 129.26 159.72 ± 185.09 26.71 ± 43.19
Median (IQR) 17.50 (62.5) 60.00 (274.5) 5 (16.3)
Poor outcome N (%) 22 (42.3) 3 (16.7) 19 (55.9) 0.008 0.025 0.27 (0.09–0.82)

B-H, Benjamini–Hochberg Adjusted P value where multiple comparisons were done. SD, standard deviation, IQR, inter-quartile range, CSF, cerebrospinal fluid, LETM, longitudinally extensive transverse myelitis, TLC, total leukocyte count

P values showing statistical significant results are marked in bold